(Q34547805)

2 August 2017

1 reference

title

Planned interruptions of anti-HIV treatment (English)

1 reference

2 August 2017

B Hirschel

1

1 reference

2 August 2017

publication date

1 August 2001

1 reference

Lancet Infectious Diseases

2 August 2017

published in

1 reference

2 August 2017

volume

1

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

53-59

1 reference

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Time to hit HIV, early and hard.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

AIDS. Boosting immunity to HIV--can the virus help?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Control of SIV rebound through structured treatment interruptions during early infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Immune control of HIV-1 after early treatment of acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

The importance of the innate immune system in controlling HIV infection and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Control of HIV despite the Discontinuation of Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Structured treatment interruptions to control HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

An in vivo model for HIV resistance development.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

AIDS research. Merck reemerges with a bold AIDS vaccine effort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

The case for more cautious, patient-focused antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2801%2900022-6

7 January 2021

10.1016/S1473-3099(01)00022-6

Identifiers

DOI

1 reference

2 August 2017

1 reference